It has been shown that ciclesonide inhibits the enzyme PAK1, a pathogenic pathway for COVID-19 related to ACE2: by inhibiting PAK1, ciclesonide reduces immune suppression and reduces lung inflammation [52]. Here, PAK1 is linked to COVID-19.